A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.

被引：0
|
作者：
Shen, Jie
Kong, Weiwei
Zhu, Sihui
Liu, Baorui
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[2] Nanjing Univ, Comprehens Canc Ctr, Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[4] Nanjing Univ, Comprehens Canc Ctr, Med Sch, Clin Canc Inst,Drum Tower Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of erlotinib in patients with advanced biliary cancer
    Philip, Philip A.
    Mahoney, Michelle R.
    Allmer, Cristine
    Thomas, James
    Pitot, Henry C.
    Kim, George
    Donehower, Ross C.
    Fitch, Tom
    Picus, Joel
    Erlichman, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3069 - 3074
  • [42] A multicenter phase II study on the feasibility and efficacy of neoadjuvant chemotherapy for locally advanced rectal cancer.
    Goto, Saori
    Hasegawa, Suguru
    Matsumoto, Takuya
    Hida, Koya
    Kawamura, Junichiro
    Yamanokuchi, Satoshi
    Yamaguchi, Takashi
    Matsusue, Ryo
    Kadokawa, Yoshio
    Kato, Shigeru
    Manaka, Dai
    Nishitai, Ryuta
    Nomura, Akinari
    Kanazawa, Akiyoshi
    Kawada, Kenji
    Kyogoku, Takahisa
    Sakai, Yoshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study
    GonzalezBaron, M
    Feliu, J
    delaGandara, I
    Espinosa, E
    Colmenarejo, A
    MartinezMartinez, B
    Blanco, E
    GarciaGiron, C
    Juarez, F
    Garrido, P
    Ordonez, A
    Zamora, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2215 - 2219
  • [44] A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
    Oh, Do-Youn
    Ryu, Min-Hee
    Hwang, Jun-Eul
    Cho, Jaeyong
    Zang, Dae Young
    Oh, Sang Cheul
    Lee, Jeeyun
    Lee, Keun-Wook
    Rha, Sun Young
    Shim, Byoung Yong
    Ho, William
    Chisamore, Michael Jon
    Rhee, Paul Dong
    Jung, Sooa
    Kim, Taewan
    Yoon, Jiyeon
    Jang, Hosung
    Baek, Eunhye
    Noh, Young Su
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [45] Efficacy and safety of anlotinib plus toripalimab as first-line regimen in advanced gastric cancer patients with performance status 2 (PS 2): An open-label, single arm, phase II trial
    Liu, K.
    Qin, B.
    Chen, S.
    Zhong, X.
    Duan, X.
    Wu, Y.
    Ling, Y.
    Sun, L.
    Shi, D.
    Jiao, X.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1469 - S1469
  • [46] A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.
    Wilmink, Johanna
    Kordes, Sil
    Zwinderman, Koos
    Mathot, Ron
    Punt, Cornelis J. A.
    Richel, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
    Larsen, Finn Ole
    Markussen, Alice
    Diness, Laura V.
    Nielsen, Dorte
    ONCOLOGY, 2018, 94 (01) : 19 - 24
  • [48] The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.
    Huang, Naisi
    Sun, Guohua
    Wang, Yulong
    Chen, Jiaying
    Guan, Qing
    Lu, Zhongwu
    Xiang, Jun
    Wei, Wenjun
    Ma, Ben
    Ji, Qinghai
    Wang, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer.
    Pusztai, L
    Nealy, KM
    Pallansch, P
    Rivera, E
    Valero, V
    Cristofanilli, M
    Hortobagyi, GN
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 285 - 285
  • [50] Phase II study of perifosine in metastatic or advanced breast cancer.
    Leighl, NB
    Warr, D
    Vandenberg, T
    Dent, S
    Tannock, IF
    Crump, M
    Tozer, R
    Dancey, J
    Moore, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S67 - S68
12345